FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine and aims at preventing, treating or managing cancer, preferentially metastatic cancer, in a patient. The method involves administering an effective amount of Axl inhibitor in a combination with an effective amount of one or more chemotherapeutic substance. The Axl inhibitor represents 1-(6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N3-(7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)-1H-1,2,4-triazole-3,5-diamine in the form of a recovered stereoisomer or a mixture thereof, or in the form of a tautomer or a mixture thereof, or their pharmaceutically acceptable salt or N-oxide. The chemotherapeutic substance is specified in a group consisting of: cisplatin, lapatinib, erlotinib, gemcitabine, doxorubicine, paclitaxel, cytarabine and docetaxel.
EFFECT: method enables increasing the clinical effectiveness in cancer, reducing side effects.
5 cl, 11 ex, 16 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| BICYCLIC PYRIDINE DERIVATIVES USEFUL AS FATTY ACID BINDING PROTEIN (FABP) 4 AND / OR 5 INHIBITOR | 2013 |
|
RU2648247C2 |
| METHOD OF RESIDUAL LIPOPROTEINS PRODUCING INHIBITION | 2004 |
|
RU2330682C2 |
| MALONAMIDE DERIVATIVES AS γ-SECRETASE INHIBITORS | 2004 |
|
RU2330849C2 |
| NEW BICYCLIC COMPOUNDS OF THIOPHENYLAMIDE | 2013 |
|
RU2644565C2 |
| SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR TREATING VESTIBULAR DISORDERS | 2009 |
|
RU2589846C2 |
| PYRIDAZINE DERIVATIVES | 2006 |
|
RU2401832C2 |
| DERIVATIVES OF 5-(AMINO-SUBSTITUTED)-1,2,4-TRIAZOLO-[1,5-A]-PYRIMIDINE, THEIR PHARMACEUTICALLY ACCEPTABLE ACID-ADDITIVE SALTS, PHARMACEUTICAL COMPOSITION SHOWING CARDIOTONIC AND CORONARY-DILATING ACTION AND A METHOD OF CARDIOTONIC AND/OR CORONARY-DILATING EFFECT ON HEART | 1992 |
|
RU2097382C1 |
| COMPOSITION FOR KERATIC FIBRE COLOURING CONTAINING AT LEAST ONE DIAMINO-N, N-DIHYDROPYRAZOLONE DERIVATIVE | 2004 |
|
RU2330909C2 |
| TYPE 1 DIACYLGLYCEROL-O-ACYLTRANSFERASE ENZYME INHIBITORS | 2008 |
|
RU2486186C2 |
| ANTIVIRAL REMEDIES FOR TREATMENT AND PREVENTION OF HIV INFECTION | 2020 |
|
RU2780101C2 |
